Yes this is good. Lykiri is reminding us all that the outstanding Phase 1 data is at least very close to being replicated in Phase 3 based on blinded analysis. This is a tribute to the effort by Dr. Linda Liau NOT to cherry pick but to get at the actual truth about the vaccine benefit both in the middle group (Phase 3) and in the outliers like rapid and pseudo progressors in other arms. This ancillary evidence can all be used as ancillary support of approval efforts. Best wishes.
News 
Market Data 
Discover 
